Daré Bioscience, Inc. Stock News

This was the position of AAN, NLC, and PSI in a joint statement at the Launch of Research Report with the theme ‘Who Cares for the Future; Finance Gender Responsive Public Services’ held in Abuja.

Dare Bioscience (NASDAQ:DARE)‘s stock had its “buy” rating reaffirmed by analysts at Maxim Group in a report released on Thursday, AnalystRatings.com reports. They currently have a $3.00 target

ELLSWORTH — Sheriff Scott Kane withdrew his request to purchase protective riot gear for his officers prior to a heated debate during Tuesday’s Hancock County Commissioners’ meeting. The board d

Here’s the answer.

Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, today announced the initiation of the DARE-BVFREE study, a multi-center, double-blind, placebo-controlled Phase 3 clinical study

Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, today announced the receipt by its wholly owned subsidiary of $1.5 million in additional grant funding from the Bill & Melinda G

Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, today announced that the company will participate in the BIO International Convention, which will be held in a new, virtual eve

Q1 2020 Dare Bioscience Inc Earnings Call

Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, today reported financial results for the first quarter ended March 31, 2020 and provided a company update. “The first quarte

Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, and Health Decisions, Inc., a full-service contract research organization (CRO) specializing in women’s health clinical resear

The smid-cap biotech earnings deluge hit Wall Street in the week ended May 9, positively impacting the stocks in the sector. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB)...

Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, May 14, 2020, to

Broadwind Energy (NASDAQ:BWEN) +60%. on $19M order.TrovaGene (NASDAQ:TROV) +44% on new positive results from its ongoing Phase 1b/2 clinical trial of onvansertib in combination with FOLFIRI and Avast

Daré Bioscience, Inc.(DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, President and Chief Executive Officer, will participate in a panel discussion dur

Adverum Biotechnologies (NASDAQ:ADVM) initiated with Buy rating and $17 (36% upside) price target at Goldman Sachs.Alector (NASDAQ:ALEC) initiated with Buy rating and $32 (21% upside) price target at